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MicroRNAs (miRNAs) are single-stranded, non-coding RNA molecules that 
regulate gene expression via imperfect binding of the miRNA to specific sites in 
the 3' untranslated region of the mRNAs. Because prediction of miRNA targets is 
an essential step for understanding the functional roles of miRNAs, many 
computational approaches have been developed to identify miRNA targets. 
However, identifying targets remains challenging due to the inherent limitation of 
current prediction approaches based on imperfect complementarity between 
miRNA and its target mRNAs. To overcome these current limitations, we 
developed a novel correlation-based approach that is sequence independence to 
predict functional targets of miRNAs by step-wise integration of the expression 
data of miRNAs, mRNAs, and proteins from NCI-60 cell lines. A correlation 
matrix between expression of miRNAs and mRNAs was first generated and later 
integrated with the correlation matrix between expression of mRNAs and 
signaling proteins. Because these integrated matrices reflect the association of 
miRNAs and signaling pathways, they were used to predict potential signaling 
pathways regulated by certain miRNAs. We implemented a web-based tool, 
miRPP, based on our approach. As validation of our approach, we also 
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demonstrated that miR-500 regulates the MAPK pathway in melanoma and 
breast cancer cells as predicted by our algorithms. In additional experiments, we 
further identified PPFIA1 as a direct target of miR-500 that regulates MAP2K1 in 
the MAPK pathway. In conclusion, we developed a systematic analysis approach 
that can predict signaling pathways regulated by particular miRNAs. Our 
approach can be used to investigate the unknown regulatory role of miRNAs in 
signaling pathways and gene regulatory networks. 
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INTRODUCTION 
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1. MicroRNAs 
Noncoding RNAs (ncRNAs) are functional RNA molecules which are not 
translated into proteins (Cech and Steitz 2014). NcRNAs play critical roles in 
regulating gene expression at transcription, RNA processing, and translation 
levels (Bogunovic et al. 2009) in various biological processes. Depending on the 
length and functions, ncRNAs can be classified into three groups: very small 
RNAs (18 - 25 nucleotides) – microRNAs (miRNAs) and small interfering RNAs 
(siRNAs); small RNAs (smRNAs, 20-200 nucleotides); and medium and large 
RNAs (piRNAs, 200-10000 nucleotides) (Table 1)  (Wurdinger and Costa 2007; 
Esteller 2011) . 
 MicroRNAs are single-stranded noncoding RNA molecules and 
approximately 21–25 nucleotides in length, that play crucial roles in 
posttranscriptional regulation of gene expression (Bartel 2004).  MicroRNAs are 
partially or fully sequence-complementary to mRNA targets, and their main 
function is reduce stability, expression and/or translation of mRNAs in a variety of 
manners, including mRNA cleavage, translational repression, and deadenylation 
(Bartel 2009). More than 28,000 of miRNAs have been discovered in various 
organisms through both experimental sequencing and computational prediction 
in miRBase (http://miRBase.org), which provides easy access to miRNA 
sequence data, annotation data, target prediction and nomenclature (Kozomara 
et al. 2014).  
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Table 1.  Non-coding RNA types 
   
Name Size Location 
Number 
in 
humans 
Functions 
Short ncRNAs 
    
miRNAs 19–24 bp 
Encoded at 
widespread 
locations 
>1,424 Targeting of mRNAs and many 
others 
piRNAs 26–31bp Clusters, intragenic 23,439 
Transposon repression, DNA 
methylation 
tiRNAs 17–18bp Downstream of TSSs >5,000 Regulation of transcription? 
Mid-size ncRNAs 
    
snoRNAs 60–300 bp Intronic >300 rRNA modifications 
PASRs 22–200 bp 
5′ regions of 
protein-coding 
genes 
>10,000 Unknown 
TSSa-RNAs 20–90 bp −250 and +50 bp 
of TSSs >10,000 Maintenance of transcription? 
PROMPTs <200 bp −205 bp and −5 kb of TSSs Unknown Activation of transcription? 
Long ncRNAs 
    
lincRNAs >200 bp Widespread loci >1,000 Examples include scaffold DNA–chromatin complexes 
T-UCRs >200 bp Widespread loci >350 Regulation of miRNA and 
mRNA levels? 
Other lncRNAs >200 bp Widespread loci >3,000 
Examples include X-
chromosome inactivation, 
telomere regulation, imprinting 
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1-1  Biogenesis 
Most of miRNAs has known to be located in the intron region of their host genes 
and share their mRNAs and regulatory elements resulting in a similar expression 
pattern (Bartel 2009; Saj and Lai 2011). Figure 1 shows canonical biogenesis of 
miRNA (Sullivan and Ganem 2005; Ruby et al. 2007; Winter et al. 2009). The 
process has several steps to produce a mature form of a miRNA from its host 
gene. The miRNA host gene is transcribed to a large RNA precursor (pri-miRNA) 
with of a 5' cap and poly-A tail3 in nucleus, and then processed to a precursor 
miRNA (pre-miRNA) by the complex of Drosha4 (RNase III enzyme) and 
Pasha/DGCR85 (double-stranded-RNA-binding protein). The pre-miRNAs 
becomes the imperfect stem-loop structure of about 70-nucleotides in length, and 
is exported into the cytoplasm by the karyopherin exportin 5 (Exp5) and Ras-
related nuclear protein (Ran)-GTP complex. Next pre-miRNA is further 
processed to a miRNA-miRNA duplex with 22 nucleotides by the RNAse III 
enzyme Dicer. After one strand of this duplex is degraded, a mature miRNA with 
approximately 22 nucleotides is generated and binds to RNA-induced silencing 
complex (RISC) leading to gene silencing and RNA interference (Paroo et al. 
2007).  
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Figure 1. Canonical biogenesis of miRNA. miRNA genes are expressed by 
RNA polymerase II in the nucleus forming the primary miRNA (pri-miRNA).         
The stem–loop is cleaved by Drosha in conjunction with Pasha (= DGCR8 in 
vertebrates). The precursor miRNA (pre-miRNA) is transported into the 
cytoplasm by Exportin-5 (Exp 5) where it is further processed by Dicer in 
association with the loquacious protein to produce a ∼22 nt miRNA:miRNA* 
duplex. The passenger strand, miRNA*, is usually degraded and the guide strand, 
miRNA, becomes incorporated into the RNA-induced silencing complex 
(Sontheimer 2005) containing the argonaute (Ago) protein. The miRNA–RISC 
complex interacts with the target sequences leading to repression of translation, 
mRNA degradation, or upregulation of transcript levels (Asgari 2011).  
Modified from Asgari, Front Physiol. 2011 under permission from Frontiers 
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1-2 MicroRNA and mRNA target interaction  
In miRNA target prediction using sequence based computational approaches, the 
critical step is to identify the miRNA-mRNA target interaction. There are four 
main characteristics to predict this interaction as followings: seed match, 
conservation, free energy and site accessibility (Cancer Genome Atlas Research 
et al. 2013). The seed sequence of a miRNA is the first 2-8 nucleotides from the 
5' end (Asgari 2011). Most of miRNA target prediction tools use this seed 
sequence to identify the targets of a miRNA by Watson-Crick (WC) match (Asgari 
2011) (Fig.2). Base paring pattern is important to predict miRNA targets (Maziere 
and Enright 2007). The potential binding sites can be defined into three groups 
such as 5’-dominant seed canonical, 5’-dominant seed only , and 3’-
compensatory (Enright et al. 2003; Lewis et al. 2005) (Fig.3). 
 Depending on the prediction algorithms, several types of seed matches 
are used: 6 mer, 7-mer-m8, 7mer-A1, and 8mer (Brennecke et al. 2005). 
Sequence conservation across species is one of factors to predict miRNA targets. 
Generally miRNA seed regions are highly conserved compared with non-seed 
region in a miRNA (Cancer Genome Atlas 2012). Gibbs free energy in binding 
between a miRNA and its target mRNA can be used for a prediction measure. If 
it has the lower energy the stability is increased meaning more likely to be a true 
target (Nair et al. 2014).  Site accessibility of a miRNA to a mRNA target is one of 
measurements for target prediction. Depending on the secondary structure of a 
target mRNA, miRNA:mRNA hybridization can be predicted (Cancer Genome 
Atlas Research 2008). Although many miRNA target prediction algorithms have 
 been developed, it is still challengeable 
possibility per a miRNA depending on various conditions.
 
 
 
 
 
 
Figure 2. Schematic overview
nucleotides 2-8 of the miRNA seed region play an important role in binding 
target mRNA. Frank represents the outside sequence of the seed region.
wobble pair in green is 
Modified from Peterson et al.
from Frontiers 
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due to the thousands
 
 of a miRNA-mRNA target interaction
shown in the middle of the interaction.  
, Front Genet. 2014 Feb 18;5:23 with permission 
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Figure 3. Major three types of secondary structures of miRNA-mRNA 
duplex.  (A) Canonical sites with a perfect base paring , a bulge, and  an 
extensive base pairing. (B) Dominant  seed sites with perfect complementarity in 
the seed region, but poor complementarity in the 3' end. (C) Compensatory sites  
with a mismatch or G:U wobble in  the seed region, but have extensive  base 
pairing to the 3' end.  
Modified from Min and Yoon, Experimental & Molecular Medicine (2010) 42, 233-
244 with permission from BioMed Central.  
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1-3  Nomenclature of miRNA 
For thousands of miRNAs across other species, the nomenclature system has 
been used before publication of their discovery. There are conventions for 
naming miRNA (Ambros et al. 2003) (Fig.4). In annotation a miRNA 
experimentally examined has a number followed by the prefix ‘mir’ or ‘miR’ and a 
dash such as ‘mir-123’.  The ‘mir-‘  and ‘miR’ represent pre-miRNA and the 
mature form, respectively. miRNAs with similar sequences are annotated by 
adding lower case letter such as miR-1a and miR-1b. The same miRNA from 
different loci are annotated with an additional number such as miR-1-1 and miR-
1-2. The species information is preceded to a miRNA. For example, hsa-miR-142 
represents the miR-142 of homo sapience.  The miRNAs originated from the 3’ or 
5’ end are annotated with a -3p or 5p suffix such as miR-142-5p and miR-142-3p. 
  
  
  
 
Figure 4. Nomenclature of miRNA.
premature and mature 
structure of miRNA with 1 or 2 nucleotide differences (C) Additional number 
means the same miRNA from different loci. (D) “3p” and “5p” repre
originating for the 3 and 5 end. Species is preceded to miRNA nomenclature.
11 
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1-4  miRNA action mechanism 
Currently, 28645 miRNAs has been registered in miRBase (Kozomara et al. 
2014). miRNAs silence gene expression by making partial base-paring with 3’ 
untranslated region of target mRNAs (Bartel 2009). Because imperfect base-
pairing with target mRNAs is sufficient for inhibition, single miRNA can target a 
number of genes and also multiple miRNAs can target single mRNA (Vlachos et 
al. 2012).  
Figure 5 shows main regulatory mechanism of miRNAs. MicroRNAs can 
repress mRNA translation and destabilize mRNA transcripts in the processing 
body (P-body) in which miRNA-target mRNAs are isolated from translational 
process and degraded (Fazi and Nervi 2008; Romero-Cordoba et al. 2014). 
Furthermore miRNA regulation mechanisms can be classified to cis- and trans-
regulation (Liu et al. 2009) (Fig.6). In cis-regulation, miRNAs directly bind to 
target mRNA sequences and regulate the gene expression and translation. In 
trans-regulation, miRNAs can indirectly regulate from gene to protein levels by 
targeting the mRNAs of transcription factors, RNA regulating proteins and 
interacting proteins. 
  Recent studies estimated that each miRNA can regulate more than 200 
genes (Krek et al. 2005; Bussey et al. 2006; Gennarino et al. 2009), implying that 
miRNAs regulates a large number of biological processes that are frequently 
altered in many human diseases.  Therefore, to understand the functional roles 
of miRNAs in disease, it will be axiomatic to accurately identify target mRNAs.   
13 
 
 
 
 
  
 
 
 
Figure 5. Major functions of miRNAs. Mature miRNAs guide the RISC complex 
to the 3′ untranslated regions (3′-UTR) of the complementary mRNA targets. The 
complexes repress mRNA translation, degrade mRNAs and destabilize by de-
adenylation. Scissors indicate the cleavage on pri-miRNA or mRNA. RISC: RNA-
induced silencing complex.   
  
  
Target 
mRNA 
5’ 
3’  
  
 
RISC 
Translation Degradation Deadenylation 
 
 
  
 
 
 
  
 
  
 
AAAAA 
14 
 
 
 
 
  
   
A. Cis-regulation 
RNA-directed DNA methylation? 
Targeting gene promoter? 
miRNA 
Gene mRNA 
Targeting mRNA 
1. mRNA decay 
2. Inhibit translation 
miRNA 
mRNA encoding 
transcription 
mRNA encoding protein 
Regulating mRNA 
mRNA encoding 
Regulating mRNA 
Transcription factor RNA regulating protein Interacting protein 
Gene mRNA Protein 
B.   Trans-regulation 
15 
 
Figure 6.  Potential microRNA regulation mechanisms by multifactorial and 
encompassing interactions. (A) Cis-regulation. MicroRNAs directly target the 
mRNA, and control the expression of the target gene at post-transcriptional 
levels by mRNA degradation and inhibiting translation. (B) 
Transregulation. MicroRNAs regulate the expression changes of the targeted 
specific genes such as transcription factors, RNA regulating protein coding genes, 
and interacting protein coding genes. Modified from Liu et al., Comp Funct 
Genomics. 2009:837514 with permission from Hindawi publishing corporation.      
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1-5  miRNA and Cancer 
miRNAs are frequently dysregulated in many human diseases including cancer 
(Zhang et al. 2007; Lu et al. 2008; Macfarlane and Murphy 2010). Throughout 
regulating the expression of key genes in these critical pathways, miRNAs can 
modulate the cell cycle, cellular senescence, and the DNA damage response on 
tumorigenesis. The previous studies have shown that miRNAs play critical roles 
in cancer by targeting oncogenes or tumor suppressor genes (Garzon et al. 2006; 
Zhang et al. 2007) (Fig.7). When miRNAs are oncogenic, the tumor suppressor 
genes are repressed by the miRNAs resulting in tumor formation (Paranjape et al. 
2009). For example, mir-17-92, known as oncomir, was reported that enforced 
expression of mir-17-19b collaborated with the c-myc oncogene to activate B 
lymphomagenesis (He et al. 2005). 
While miRNAs also can play roles as tumor suppressor genes. In this case the 
miRNA downregulation can induce tumors. The previous studies showed 
miRNAs as a tumor suppressor gene are repressed in human cancers: colon 
cancer (Michael et al. 2003), lung cancer (Takamizawa et al. 2004), breast 
cancer (Iorio et al. 2005), and renal cell cancer (Liu et al. 2010a). For example, 
miR-20a and miR-125b have been reported to regulate the expression of E2F 
transcription factors in the retinoblastoma pathway (O'Donnell et al. 2005).  
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Figure 7. MicroRNA functions  as tumor suppressors and oncogenes. In 
cancer, aberrant miRNAs function as oncogenes by inhibiting the translation of 
tumor suppressor genes. On the other hand, tumor suppressor miRNAs are 
down-regulated resulting in the increase of oncogene expression. The both 
events  lead to tumor formation. 
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1-6  miRNA cluster 
Around 50 % of all miRNA genes are located within 50 kb in length on the 
genome and transcribed together as a cluster (Megraw et al. 2007; Becker et al. 
2012; Chan et al. 2012). These clusters range from 2 to several dozens of 
miRNAs. miRNAs in a cluster frequently shows similar sequence homology in the 
seed region. This results in identical targets of a miRNA cluster. The length of 
miRNA clusters depend on species (Chan et al. 2012). For example, mir-17 
cluster family including mir-17-92, mir-106-92, and mir-106-25, and located by 
tandem duplications (Olive et al. 2010) (Fig.8). This cluster family functions in 
cell proliferation, apoptosis, development and cancer oncogenesis (Mogilyansky 
and Rigoutsos 2013). Moreover, miRNA clusters can coordinately regulate the 
different genes or the downstream effectors such as transcription factors  in a 
specific signaling pathway or protein complex (Inui et al. 2010).  
 Because individual miRNA cluster can regulate the expression of multiple 
genes belonging to various signaling pathways, it could be a critical work to 
predict the its cellular function to target specific signaling pathways (Kuhn et al. 
2008). A miRNA cluster has been identified as cooperative regulatory RNAs 
through targeting multiple biological processes (Guo et al. 2014). They were 
evolutionary correlated and simultaneously expressed (Liang et al. 2014). 
Although the expression pattern of individual miRNA in a cluster or a family  can 
be different due to complex maturation and degradation mechanisms, a specific 
biological process can be regulated by the cluster (Xu and Wong 2008; Guo et al. 
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2014). Therefore, the integrative analysis based on clustered miRNAs might be a 
useful approach to discover the potential functional roles in tumorigenesis. 
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Figure 8. Human mir-17-92 as a polycistronic miRNA cluster and its 
homologues. Gene structure of mir-17-92 consist of miR-17, -18a, -19a, -20a, -
19b-1, and -92a-1 on chromosome 13. The mir-17-92 cluster has  two paralogs 
such as mir-106a-363 and mir-106b-25 clusters. Based on seed sequences, 
these miRNA clusters can be divided  to four miRNA families as followings: miR-
17 family (miR-17, miR-20a, miR-20b, miR-106a, miR-106b, and miR-93), the 
miR-18 family (miR-18a and miR-18b), the miR-19 family (miR-19a, miR-19b-1, 
and miR-19b-2) and the miR-92 family (miR-92a-1, miR-92a-2, miR-383, and 
miR-25). Modified from Olive et al., Int J Biochem Cell Biol. 2010 Aug;42(8): 
1348-54 with permission from Elsevier.  
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1-7  miRNA and clinical application 
 
MicroRNAs play critical roles in cancer and can be used as prognostic or 
diagnostic markers (Hung et al. 2014; Shah and Chen 2014; Ye and Cao 2014). 
Therapeutic approaches using miRNAs have been performed by re-introduction 
of miRNAs as tumor suppressors, or inhibition of oncogenic miRNAs (Jansson 
and Lund 2012). The expression profiles of miRNAs have been shown stable and 
unique signatures in the different tissue types and the stages of cancers (Lu et al. 
2005; Olson et al. 2009; Iorio and Croce 2012a; Iorio and Croce 2012b) . This 
tissue specificity of miRNA expression patterns showed  the possibility to identify 
the primary origin of metastatic cancer (Rosenfeld et al. 2008; Paranjape et al. 
2009; Ferracin et al. 2011). MicroRNAs also can be applied to discover non-
invasive biomarkers, and can measure therapeutic effect in cancer (Chen et al. 
2008; Ng et al. 2009; Paranjape et al. 2009). For these clinical application, multi-
omic data analysis including miRNA data might be useful in deciphering cancer 
biology (Fig.9).  
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Figure 9. MicroRNAs as potential diagnostic biomarkers. In cancer diagnosis, 
miRNAs can be a useful tool to provide several features. MicroRNA expression 
profile in cancer can be used to identify cancer from normal tissues and the 
original tissue for cancer. Moreover, their expression patterns in one cancer type 
show unique, and it allows to distinguishing tumor subtype. For a diagnostic test 
blood-based miRNA expression patterns can be used as a not-invasive method. 
SNPs in miRNA genes, binding sites, and the genes of a specific pathway also 
can be used to predict cancer predisposition. Modified from Paranjape et al.,Gut 
2009;58:1546-1554 with permission from BMJ Publishing Group Ltd & British 
Society of Gastroenterology. 
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2. miRNA database and target prediction 
 
 Many computational prediction approaches using sequence complementarity 
have been developed with moderate success in identifying miRNA targets (Chu 
et al. 2013(Krek et al. 2005; Griffiths-Jones et al. 2008; Maragkakis et al. 2009; 
Betel et al. 2010; Dweep et al. 2011; Iorio and Croce 2012b; Hamzeiy et al. 
2014). However, finding true targets is still extremely challenging because of 
inherited limitation of current prediction approaches based on imperfect 
complementarity between miRNA and its target mRNAs and a lack of a 
sufficiently large group of experimentally validated targets of miRNAs that can be 
used as a robust training set for target prediction (Rajewsky 2006).  
Therefore the integrated approaches using experimental and computational 
analysis has been developed to identify a true target of a miRNA  and miRNA 
databases have been constructed (Fig.10) (Table2,3). 
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Figure 10. Schematic flow to identify miRNA targets using in-vitro and in-
silico approaches. Putative target genes predicted by biochemical isolation of 
the miRISC or by target prediction algorithms are more than hundreds of 
candidates. Then, these genes can be evaluated  experimentally. Modified from 
Thomas et al., Nature Structural & Molecular Biology 17, 1169–1174 (2010) with 
permission from Nature publishing group. 
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2-1 Prediction tools 
Many miRNA target prediction tools have been developed based on their own 
detection algorithms (Table.3). miRbase is a well-known miRNA database to 
offer the information of miRNA sequences, annotations and computationally 
predicted targets linked to other prediction tools (Bussey et al. 2006). For 
predicting miRNA targets RNAHybrid used the minimum free energy (MFE) of 
hybridization between target genes and miRNA sequences  (Kruger and 
Rehmsmeier 2006) (http://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid). 
TargetScan used the sequence conservation scores calculated from the 6-8 mer 
sites of the seed region on target genes against a miRNA (Lewis et al. 2005). On 
the other hand, Tarbase provides experimentally validated target information 
(Deschenes-Simard et al. 2014). 
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Table 2.  MicroRNA databases  
 
Name of the 
database URL  Main features  Reference 
mirBase http://microrna.sanger.ac.uk 
miRNA sequences, 
annotations and 
computationally 
predicted targets 
(Bussey et al. 
2006) 
Argonaute http://www.ma.uni-heidelberg.de/apps/zmf/argonaute/interface/ 
Detailed 
information about 
known miRNAs 
and their targets 
(Liu et al. 
2010b) 
miRNAMap http://mirnamap.mbc.nctu.edu/tw 
Known as 
computationally 
predicted miRNAs 
and their targets 
(Nishizuka et 
al. 2003) 
Tarbase http://www.diana.pcbi.upenn.edu/tarbase.html 
Experimentally 
verified miRNA 
targets 
(Deschenes-
Simard et al. 
2014) 
Arabidopsis 
Small RNA 
project 
Database 
http://asrp.cgrb.oregonstate.edu/ 
Arabidopsis miRNA 
sequences and 
corresponding 
target genes in 
addition to other 
small RNAs 
(Akbani et al. 
2014) 
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Table 3 . MicroRNA target prediction algorithms  
Software Name URL Reference(s) 
TargetScan, 
TargetScanS http://genes. mit.edu/targetscan/ (Asgari 2011) 
miRanda 
http://www.microrna.org/ 
http://www.ebi.ac.uk/enrightsrv/microcosm/htdo
cs/targets/v5/ 
(Fazi and Nervi 2008) 
Pictar http://pictar.bio.nyu.edu/ (Olive et al. 2010) 
TargetBoost http://demo1.interagon.com/targetboost/ (Peterson et al. 2014) 
DIANA-microT http://diana.pcbi.upenn.edu/DIANA-microT 
(Maragkakis et al. 
2009; Maragkakis et 
al. 2011) 
Rna22 http://cbsrv.watson.ibm.com/rna22.html (Miranda et al. 2006) 
PITA http:// genie.weizmann.ad.il/pubs/mir07 (Tibes et al. 2006) 
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2-2 Limitation of DNA sequence based prediction 
For miRNA target prediction, most computational methods used the nucleotide 
sequences with perfect seed complementarity to miRNA, and the predicted 
secondary mRNA structure or energetically favorable hybridization sites (Martin 
et al. 2007; Deschenes-Simard et al. 2014). Table 3 and 4 show the features of 
the prediction tools publicly available such as TargetScan (Lewis et al. 2005), 
miRanda (John et al. 2004), PicTar (Lall et al. 2006), DIANA-micorT (Maragkakis 
et al. 2009), rna22 (Miranda et al. 2006). The prediction of miRNA targets based 
on nucleotide sequence generated many putative targets that cannot be 
experimentally validated  (Sethupathy et al. 2006). They have high false positive 
rates in target prediction up to 40% (Table 4). 
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Table 4. Summary for miRNA target prediction 
Name Target 
species Algorithms performance 
Distinguishing 
feature 
TargetScan Vertebrates Seed 
complementarity 
FPR: 22% 
(mammal) 
Requires 6-nt 
seed match and 
conserved 
Adenosine 
miRanda Flies, 
vertebrates Complementarity 
FPR: 24-39% 
(Fly) 
Also provides the 
expression 
profile of miRNA 
in various tissues 
PicTar Vertebrates, flies Thermodynamics FPR: 30% 
Uses cross-
species 
comparisons 
to filter out false 
positives 
DIANA-
microT Any Thermodynamics 
Precision: 
66% 
Target structure 
comes before 
seed 
complementarity 
rna22 Any Pattern 
recognition 
FPR: 19-
25.7% 
Sensitivity: 
83% 
Eliminates the 
use of cross- 
species 
conservation 
filtering, 
and leads to 
putative targets 
sites in 5’ UTRs 
and ORF 
 
Modified from Experimental & Molecular Medicine (2010) 42, 233-244 with 
permission from Nature publishing group 
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2-3 Modified prediction  
Recent studies proposed new approaches that integrate transcriptomic data into 
complementary seed sequence data to overcome the current limitation by using 
a combination of target predictions and paired miRNA-mRNA expression 
patterns in the same tissues and cells (Liu et al. 2007; Wang et al. 2009; Wang 
and Li 2009) (Table 5).  However, predicted outcomes of many different 
prediction algorithms are frequently inconsistent, suggesting that finding a true 
miRNA target is still very challenging (Witkos et al. 2011). Moreover, 
understanding molecular functions of miRNAs are further hampered by the fact 
that many of predicted targets are poorly annotated. 
 
2-4 New challenges   
Recent studies demonstrated an association between miRNAs and expression of 
target proteins (Betel et al. 2010), suggesting that protein expression profile data 
can be used to verify putative functional targets and potential molecular networks 
regulated by miRNA (Baek et al. 2008; Selbach et al. 2008). Because proteins 
are functional end products of miRNA targets, proteomic approaches for 
identifying miRNAs targets would significantly improve our understanding on 
functional roles of miRNAs.  
  
  
Adapted from 
3. RPPA and signaling pathway
 
Reverse phase protein arrays (RPPA) is a powerful high
with the procedures similar to that of Western blots for targeted proteomics 
(Hennessy et al. 2010)
number of samples at the same time against high
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quantitative manner. As a major advantage, RPPA allows to assess target 
protein expression quantitatively in large sample sets while requiring only a very 
low amount of biological sample making this platform attractive for the analysis of 
clinical materials and biomarker discovery. 
 Furthermore, because proteomic data include critical signaling events 
such as phosphorylation, acetylation, and sumoylation of proteins (Nishizuka et 
al. 2003; Park et al. 2010), functional roles of miRNAs in key signaling pathways 
can be readily uncovered by correlating miRNAs with proteomic data. 
 
4. NCI-60 cells and data sets 
 In this study, we sought to integrate expression data of miRNAs, mRNAs, and 
proteins to uncover signaling networks regulated by miRNAs and key regulatory 
genes (mRNAs) of the networks directly targeted by miRNAs.  We used data 
from panel of NCI-60 cancer cells that have been extensively used for genomic 
and pharmacological studies (Ross et al. 2000; Tibes et al. 2006; Blower et al. 
2007; Shankavaram et al. 2007). The NCI-60 cells consist of leukemia, 
lymphoma, and ovarian, renal, breast, prostate, colon, lung, and central nervous 
system carcinoma cells(Table.6). NCI-60 is also the most extensively profiled set 
of cells, and investigators have widely used them in many cancer-related studies. 
In recent study (Park et al. 2010), we generated extensive proteomic data from 
NCI-60 cell lines by using the RPPA technique.  
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5. Motivation and aims  
Identification of miRNAs’ target genes has been challenging because of inherited 
limitation of current prediction methods that are largely based on imperfectly 
matched short sequences between miRNAs and their target sequences. 
Because mRNAs indirectly regulate protein expression or activation by targeting 
their mRNAs, we aimed to develop prediction approach that would mimic 
biological process of regulatory circuits in cells.  
To uncover the complicated intracellular signaling networks regulated by miRNAs, 
we carried out multi-step integrated analyses with both transcriptome and 
proteome data from cancer cell lines.  
 
In this study we aimed as the following: 
• First, to develop a new approach for the integration of three independent 
datasets in NCI-60 data. 
• Second, to establish a prediction model for identifying putative direct or 
indirect miRNA targets by integrating genomic and proteomic data, and to 
construct a web-based database  
• Third, to validate a prediction model that miRNAs are highly associated with 
biological signaling pathway by in-vitro experiment. 
• Last, to construct a web-based database to provide the data analysis outputs 
by our approach 
 
  
 
 
 
Figure11. Gene–protein network in normal tissues and in cancer.
are transcribed from miRNA non
multiple mRNAs affecting the output of many proteins. miRNAs have a crucial 
role in keeping the gene
miRNA and mRNA expression 
oncogenic proteins that cause a certain cancer phenotype.
coordinate gene regulatory networks at genomic and proeomic level.
Adopted from Garzon et al., 
with permission from Nature publishing group
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CHAPTER 2 
MATERIALS AND METHODS 
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1. The datasets 
The mRNA expression data of NCI-60 cell lines (Table.6) were generated by 
using Affymetrix HG-U133 44K platform and available from Gene Express 
Omnibus (GEO) database (accession number, GSE5720). MiRNA expression 
data were generated by using custom-made microarray from Ohio State 
University Comprehensive Cancer Center (OSU-CCC-hsa-miRNA-chip-V3) and 
available from ArrayExpress (accession number E-MEXP-1029) (Blower et al. 
2007). This microarray contains 627 probes representing 423 unique 
miRNAs.  Protein expression data were generated by using custom-made RPPA 
from University of Texas MD Anderson Cancer Center as described in Park et al 
(Park et al. 2010). RPPA platform contains 167 unique protein features.  
 
2. Data preprocessing 
The mRNA and miRNA data sets were log2 transformed and normalized using 
quantile normalization in Bioconductor (www.bioconductor.org). As a large 
fraction of mRNAs and miRNAs were either not expressed or non-detectable, we 
filtered out 30% of total probes with low variance across all samples to reduce 
potential noise. The final number of mRNA and miRNA probes reduced to 25,306 
and 436 probes for final data analysis respectively. Multiple values from multiple 
probes map to single genes by calculating the average of their values. 
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Table 6.  Tumor tissue types of NCI-60 cell lines* 
* http://discover.nci.nih.gov/cellminer 
 
Tissue of 
origin  
Cell Line 
Name 
Age Sex Histology Source p53 
doubling 
time 
Breast BT_549 72 F 
Papillary infiltrating ductal 
carcinoma-mammary gland; 
breast 
Metastasis - 53.9 
Breast HS578T 74 F 
Carcinosarcoma-mammary 
gland; breast 
Primary MT 53.8 
Breast MCF7 69 F 
Adenocarcinoma- mammary 
gland; breast; metastatic 
site: pleural effusion; 
Pleural 
effusion 
WT 25.4 
Breast MCF_7/AdrR NA F Adenocarinoma NA MT 34 
Breast MDA_MB_231 51 F 
Adenocarcinoma-mammary 
gland; breast; epithelial; 
metastatic site 
Pleural 
effusion 
MT 41.9 
Breast MDA_MB_435 31 F 
Ductal carcinoma- mammary 
gland; breast; duct; 
metastatic site 
Pleural 
effusion 
MT 25.8 
Breast T47D 54 F infiltrating ductal carcinoma NA MT 45.5 
CNS SF_268 24 F Glioblastoma, ud NA MT 33.1 
CNS SF_295 67 F Glioblastoma, ud NA MT 29.5 
CNS SF_539 34 F Glial cell neoplasm NA WT 35.4 
CNS SNB_19 47 M Glioblastoma, ud NA MT 34.6 
CNS SNB_75 NA F Astrocytoma NA MT 62.8 
CNS U251 75 M Glioblastoma,ud NA MT 23.8 
Colon COLO205 70 M Adenocarcinoma Ascites MT 23.8 
Colon HCC_2998 NA NA carcinoma NA MT 31.5 
Colon HCT_116 NA M carcinoma-vpd NA - 17.4 
Colon HCT_15 NA NA Adenocarcinoma p/md NA - 20.6 
Colon HT29 44 F Adenocarcinoma-md Primary MT 19.5 
Colon KM12 NA NA Adenocarcinome-pd NA MT 23.7 
Colon SW_620 51 M Carcinoma-ud NA MT 20.4 
Leukemia CCRF_CEM 4 F ALL NA MT 26.7 
Leukemia HL_60 36 M Pro myelocytic leukemia PBL MT 28.6 
Leukemia K_562 53 F CML 
Pleural 
effusion 
MT 19.6 
Leukemia MOLT_4 19 M 
ALL (cells were taken when 
patient was in relapse) 
PB WT 27.9 
Leukemia RPMI_8226 61 M Myeloma PB WT 33.5 
Leukemia SR 11 M Lymphoma NA - 28.7 
Melanoma LOXIMVI 58 M 
Malignant amelanotic 
melanoma 
NA WT 20.5 
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Melanoma M14 NA NA Melanotic melanoma NA MT 26.3 
Melanoma MALME_3M 43 M 
Malignant melanotic 
melanoma 
Metastasis WT 46.2 
Melanoma SK_MEL_2 60 M 
Malignant melanotic 
melanoma 
Metastasis WT 45.5 
Melanoma SK_MEL_28 51 M 
Malignant melanotic 
melanoma 
NA MT 35.1 
Melanoma SK_MEL_5 24 F 
Malignant melanotic 
melanoma 
Metastasis WT 25.2 
Melanoma UACC_257 NA NA Melanotic melanoma NA WT 38.5 
Melanoma UACC_62 NA NA Melanotic melanoma NA WT 31.3 
Non-Small 
Cell Lung 
A549 58 M Adenocarcinoma-p/md NA WT 22.9 
Non-Small 
Cell Lung 
EKVX NA M Adenocarcinoma-md NA MT 43.6 
Non-Small 
Cell Lung 
NCI_H226 NA M 
Squamous cell carcinoma-
vpd 
NA MT 61 
Non-Small 
Cell Lung 
NCI_H23 NA M Adenocarcinoma-ud NA MT 33.4 
Non-Small 
Cell Lung 
NCI_H322M 52 M 
Small cell Bronchioalveolar 
Carcinoma 
NA MT 35.3 
Non-Small 
Cell Lung 
NCI_H460 NA M Large Cell Carcinoma-ud 
Pleural 
effusion 
WT 17.8 
Non-Small 
Cell Lung 
NCI_H522 NA M Adenocarcinoma-vpd NA MT 38.2 
Non-Small 
Cell Lung 
HOP_62 60 F adenocarcinoma-ud NA MT 39 
Non-Small 
Cell Lung 
HOP_92 62 M Large cell-ud NA MT 79.5 
Ovarian IGROV1 47 F Cystoadenocarcinoma-pd NA MT 31 
Ovarian OVCAR_3 60 F Adenocarcinoma-md Ascites MT 34.7 
Ovarian OVCAR_4 42 F Adenocarcinoma-md NA WT 41.4 
Ovarian OVCAR_5 67 F Adenocarcinoma-wd NA MT 48.8 
Ovarian OVCAR_8 64 F Carcinoma-ud NA MT 26.1 
Ovarian SK_OV_3 64 F Adenocarcinoma-vpd Ascites - 48.7 
Prostate DU_145 69 M 
prostate; metastatic site: 
brain; carcinoma  
Metastasis - 32.3 
Prostate PC_3 62 M 
Adenocarcinoma- prostate; 
metastatic site: bone; 
NA MT 27.1 
Renal 786_0 58 M Adenocarcinoma NA MT 22.4 
Renal A498 52 F Adenocarcinoma NA WT 66.8 
Renal ACHN 22 M Renal cell carcinoma-p/md NA WT 27.5 
Renal CAKI_1 49 M Clear cell carcinoma Metastasis WT 39 
Renal RXF_393 54 M hypernephroma-pd NA MT 62.9 
Renal SN12C 43 M Renal cell carcinoma-pd NA MT 29.5 
Renal TK_10 43 M Renal Spindle cell carcinoma NA MT 51.3 
Renal UO_31 NA F Renal cell carcinoma-vpd NA WT 41.7 
 3. Correlation analysis between miRNA
To identify the functional targets of miRNA, Pearson’s correlation coefficient 
approach applied to the miRNA, mRNA and protein array data generated from 
NCI-60 cell lines. The log
the association among the expression pro
the correlation coefficient values among all miRNA, mRNA and protein 
expression profiles; all
Overall data process is shown in Fig
between two data sets was calculated by
 
 
where X denotes expression value of a miRNA or a protein, and Y denotes 
expression value of a mRNA. 
the standard deviations of all X and Y values of each probe. We defined the 
miRNA-mRNA correlation coefficient 
significant. 
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4. Generation of miRNA and Pathway association 
To establish the association between miRNAs and signaling pathways, we 
carried out multi-step data analyses and integrated analyzed outcomes. We 
started this process by generating association score. First, we computed 
correlation between miRNAs and mRNAs by using Pearson correlation test with 
stringent cut-off (P < 0.005). Likewise, correlation between protein features and 
mRNAs were computed by using Pearson correlation test (P < 0.005). Second, in 
order to estimate the association between miRNA and protein, two independently 
generated correlation lists (miRNAs and protein features) were merged together 
by using correlated mRNAs as denominators. Computed association scores were 
saved in matrix format (222 RPPA probes x 436 miRNA = 96,792) for further 
analysis (association score matrix or ASM). In ASM, correlation between miRNAs 
and protein features were represented as number of commonly shared correlated 
mRNAs. For example, if miRNA-X and RPPA-Y has 5 correlated mRNAs 
respectively and share 3 mRNAs, association score between miRNA-X and 
RPPA-Y will be 3 (Fig. 12).   
  
  
 
 
 
 
Figure 12. Schematic diagram for Association Scores
number of commonly shared correlated mRNAs between miRNAs and protein 
features. For example, if miRNA
respectively and share 3 mRNAs, association score between miRNA
RPPA-Y will be 3. Finally
between miRNAs and RPPA proteins.
 
42 
 (AS) was estimated by 
-X and RPPA-Y has 5 correlated mRNAs 
 Association Scores Matrix (ASM) was generated 
 
 
-X and 
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Next, we assessed significance of signaling events in NCI-60 cells by estimating 
correlated number of mRNAs with phosphorylation of signaling proteins. To 
estimate the signaling influence we assumed that a phosphorylated protein might 
be more impact on gene expression more than its unmodified form in signaling 
pathway. 
RPPA data includes 25 pairs of antibodies that can specifically recognize 
phosphorylated or unmodified same proteins. Establishing a Pearson’s 
correlation test P-value of less than 0.005 as indicative of significance with 
expression or phosphorylation patterns of the each protein feature, we first 
generated lists of correlated mRNAs for expression (unmodified form)) and 
phosphorylation level (modified form) of proteins. Second, with paired numbers of 
mRNAs significantly associated with phosphorylated and unmodified protein, P/U 
ratios (number of mRNAs associated with phosphorylated protein/number of 
mRNAs associated with unmodified protein) were generated and used as 
indicator of signaling activity of particular protein in NCI-60 cell lines.  For 
example, if number of mRNAs correlated with phosphorylation of particular 
protein (P value) is 9 and number of mRNAs correlated with unmodified same 
proteins (U value) is 3, then P/U ratio of the protein will be 3 (Fig.13 ).  
We also identified signaling pathways that are potentially regulated by 25 
signaling proteins in RPPA data (Table 7).  
  
  
 
 
 
Figure 13 . Schematic diagram for generation of P/U ratios.
signaling influence weight, P/U ratio. It was calculated by P/U ratios (number of 
mRNAs associated with phosphorylated protein/number of mRNAs associated 
with unmodified protein). For exam
phosphorylation of particular protein (P value) is 9 and number of mRNAs 
correlated with unmodified same proteins (U value) is 3, then P/U ratio of the 
protein will be 3. 
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Table 7.  Phosphorylation specific probe information of RPPA data  
No Gene Phospho-sepcific probe 
1 ACACA PS79 
2 AKT1 PS473/ PT308 
3 EIF4EBP1 PS65/ PT37.46 
4 ERBB2 PY1248 
5 ESR1 PS167/ PS118 
6 FOXO3 PS318.S321 
7 FRAP1 PS2448 
8 GSK3A PS21.S9 
9 IRS1 PS307 
10 MAP2K1 PS217.S221 
11 MAPK1 PMAPK1/PMAPK8/JNK 
12 MAPK14 PT180.Y182 
13 MYC PT58.S62 
14 PDK1 PS241 
15 PRKAA1 PT172 
16 PRKCA  PS567 
17 RPS6 PS235.S236/ PS240.S244 
18 RPS6KA1 PT389.S363 
19 RPS6KB1 PT389 
20 SGK PS78 
21 SRC PY416/ PY527 
22 STAT3 PS727/ PY705 
23 STAT5A PY694 
24 STAT6 PY641 
25 TSC2 PT1462 
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To do this, we carried out pathway enrichment analysis after mapping 25 proteins 
in signaling pathways by using the DAVID bioinformatics resource 
(http://david.abcc.ncifcrf.gov/) in NIAID, NIH. We used a significance threshold P-
value adjusted by Benjamini of 0.05 for KEGG and BIOCARTA pathways to 
control the false discovery rate (Huang da et al. 2009). This analysis showed that 
40 signaling pathways can be potentially regulated by 25 signaling proteins 
(Table 8).  
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Table 8. Significantly enriched signaling pathways with 25 P/U pair 
proteins† 
Pathway DB Count Genes –NP/P pair protein PValue Bonferroni Benjamini 
ErbB signaling pathway 
KEGG 
12 
PRKCA, AKT1, MAPK1, EIF4EBP1, 
MAP2K1, ERBB2, STAT5A, MAPK8, 
RPS6KB1, MTOR, MYC, SRC  
2.20E-14 1.47E-12 1.47E-12 
Insulin signaling pathway  
KEGG 
11 
AKT1, MAPK1, EIF4EBP1, 
MAP2K1, TSC2, ACACA, MAPK8, 
PRKAA1, RPS6KB1, MTOR, IRS1  
1.06E-10 7.12E-09 2.37E-09 
mTOR signaling pathway  
KEGG 
8 
AKT1, MAPK1, EIF4EBP1, 
RPS6KA1, TSC2, PRKAA1, 
RPS6KB1, MTOR  
1.67E-09 1.12E-07 2.79E-08 
Neurotrophin signaling pathway  
KEGG 
9 
PDK1, AKT1, MAPK1, RPS6KA1, 
MAP2K1, MAPK14, MAPK8, 
FOXO3, IRS1  
3.60E-08 2.41E-06 4.82E-07 
Regulation of eIF4e and p70 S6 Kinase   8 PRKCA, AKT1, MAPK1, EIF4EBP1, MAPK14, RPS6KB1, MTOR, IRS1  2.04E-08 2.85E-06 2.85E-06 
Fc epsilon RI signaling pathway  KEGG 7 PDK1, PRKCA, AKT1, MAPK1, MAP2K1, MAPK14, MAPK8  8.80E-07 5.90E-05 6.55E-06 
Adipocytokine signaling pathway  KEGG 6 AKT1, MAPK8, PRKAA1, MTOR, IRS1, STAT3  9.56E-06 6.41E-04 5.34E-05 
VEGF signaling pathway  KEGG 6 PRKCA, AKT1, MAPK1, MAP2K1, MAPK14, SRC  1.67E-05 0.001118 8.60E-05 
GnRH signaling pathway  KEGG 6 PRKCA, MAPK1, MAP2K1, MAPK14, MAPK8, SRC  6.13E-05 0.0041 2.42E-04 
MAPK signaling pathway  KEGG 8 PRKCA, AKT1, MAPK1, RPS6KA1, MAP2K1, MAPK14, MAPK8, MYC  1.21E-04 0.008048 4.49E-04 
Human Cytomegalovirus and Map Kinase 
Pathways  
BIOCARTA 5 AKT1, MAPK1, MAP2K1, MAPK14, RB1  3.74E-05 0.005223 0.001744 
Links between Pyk2 and Map Kinases  BIOCARTA 6 PRKCA, MAPK1, MAP2K1, MAPK14, MAPK8, SRC  2.77E-05 0.003871 0.001938 
Bioactive Peptide Induced Signaling Pathway BIOCARTA 6 PRKCA, MAPK1, MAP2K1, MAPK14, STAT5A, MAPK8  5.77E-05 0.008041 0.002016 
Fc gamma R-mediated phagocytosis  KEGG 5 PRKCA, AKT1, MAPK1, MAP2K1, RPS6KB1  7.71E-04 0.050366 0.002458 
Toll-like receptor signaling pathway  KEGG 5 AKT1, MAPK1, MAP2K1, MAPK14, MAPK8  9.71E-04 0.063027 0.002955 
Multiple antiapoptotic pathways from IGF-1R 
signaling lead to BAD phosphorylation  
BIOCARTA 5 AKT1, MAPK1, RPS6KA1, MAP2K1, IRS1  1.10E-04 0.015258 0.00307 
Transcription factor CREB and its 
extracellular signals  
BIOCARTA 5 PRKCA, AKT1, MAPK1, RPS6KA1, MAPK14  1.10E-04 0.015258 0.00307 
Chemokine signaling pathway  KEGG 6 AKT1, MAPK1, MAP2K1, GSK3A, FOXO3, STAT3  0.00125 0.080358 0.003345 
T cell receptor signaling pathway  KEGG 5 PDK1, AKT1, MAPK1, MAP2K1, MAPK14  0.001248 0.080275 0.003481 
NFAT and Hypertrophy of the heart 
(Transcription in the broken heart)  
BIOCARTA 6 AKT1, MAPK1, MAP2K1, MAPK14, MAPK8, RPS6KB1  1.64E-04 0.02276 0.00383 
Top 20 of 40 Pathways (Bejamini-Hochberg procedure, corrected P-value  < 0.05) 
† Proteins with a pair of non-phospho and phospho protein in the protein array data  
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By using analyzed outcomes from previous steps, we next to find signaling 
pathways associated with each miRNA. First, we generated matrix of miRNAs vs. 
P/U ratios of each proteins by using association scores in ASM from previous 
analysis. Among 222 antibodies used in RPPA data, we only selected 25 pairs of 
antibodies for analysis. P/U ratios were generated by using number of associated 
mRNAs from ASM. In this new matrix (436 miRNAs x 25 P/U ratios of signaling 
proteins), signaling strength of each proteins per each miRNA is presented as 
P/U ratios. Second, under the assumption that a protein with higher P/U ratio 
would play more active roles in regulation of signaling pathway, we computed the 
sum of P/U ratios of the proteins in each signaling pathway per miRNA, 
generating Pathway Association Score (PAS) (Fig.14).  PASi per a miRNA, i, 
was calculated as following: 
PASi  ∑ R	  
 
Where n is the total number of protein pairs belonging to a specific pathway and 
R is the P/U ratio value of each protein pair. For example, if there are 12 proteins 
with P/U ratios in a specific pathway, we can calculate the sum of the 12 P/U 
ratio values as a PAS per a miRNA. We computed PAS values for 40 signaling 
pathways for all miRNAs, yielding new matrix of 436 miRNAs x 40 signaling 
pathways (Pathway Association Score Matrix, PASM).  In later analysis, we used 
the ranked PAS values as indicator of signaling strength associated with miRNAs.   
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Figure  14. miRNA-Pathway association score. MicroRNA-Pathway 
association score. After generating Association Score Matrix (ASM) between 
miRNAs (Mi) and P/U ratios (Ri) of each protein, we computed the sum of P/U 
ratios of the proteins in each signaling pathway per each miRNA and calculated 
Pathway Association Score (PAS) that indicated the association of miRNAs to 
signaling pathways. Next, the matrix of PAS (PASM) was constructed. Diagram 
represents the sample pathway as following: circle-pathway.I, square-pathway.II, 
and triangle-pathway. AS: Association Score, PAS: Pathway Association Score, 
Mi: a miRNA, Ri: AS ratio of P/U protein pair, and Sik: PAS between miRNA Mi 
and Pathway k. 
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5. miRNA cluster enrichment analysis  
Previous study identified miRNA clusters in human genome (52 clusters) (Ruepp 
et al. 2010) (Table 9). Because miRNAs of the same cluster have been known to 
share common target mRNAs and similar biological function (Gurtan and Sharp 
2013), we carried out enrichment analysis of miRNAs with pathways by using 
values in PASM and miRNA genome cluster information in order to identify the 
signaling pathways potentially regulated by miRNA. 
 For the miRNA-pathway enrichment test we used the modified parametric 
analysis of gene set enrichment algorism (Kim and Volsky 2005).  For each 
pathway, j, we calculated the enrichment score (Kim and Volsky 2005) based on 
PASM as following: 

 
Ux  Ut  √N
S
 
 
where Ux denotes the mean PAS values within each miRNA cluster. Ut denotes 
the mean of PAS against all miRNAs. N denotes the number of all miRNAs and S 
denotes the standard deviation of all PAS values against each pathway. 
Enrichment score f converted into P-value by applying the cumulative standard 
normal distribution function using T-profiler algorithm (Boorsma et al. 2005) in R. 
Finally we generated the pathway-miRNA cluster association matrix (52 miRNA 
clusters x 40 pathways). Significant pathway enriched miRNA clusters were 
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selected based on the P < 0.05. All analyses were performed using the R 
Bioconductor statistical programming platform (http://bioconductor.org). 
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Table 9. MicroRNA cluster family  
Cluster  miRNA cluster   
1 
hsa-mir-371|hsa-mir-372|hsa-mir-373|hsa-mir-512-1|hsa-mir-512-2|hsa-mir-
498|hsa-mir-520e|hsa-mir-515-1|hsa-mir-519e|hsa-mir-520f|hsa-mir-515-
2|hsa-mir-519c|hsa-mir-520a|hsa-mir-526b|hsa-mir-519b|hsa-mir-525|hsa-
mir-523|hsa-mir-518f|hsa-mir-520b|hsa-mir-518b|hsa-mir-526a-1|hsa-mir-
520c|hsa-mir-518c|hsa-mir-524|hsa-mir-517a|hsa-mir-519d|hsa-mir-521-
2|hsa-mir-520d|hsa-mir-517b|hsa-mir-520g|hsa-mir-516b-2|hsa-mir-526a-
2|hsa-mir-518e|hsa-mir-518a-1|hsa-mir-518d|hsa-mir-516b-1|hsa-mir-518a-
2|hsa-mir-517c|hsa-mir-520h|hsa-mir-521-1|hsa-mir-522|hsa-mir-519a-
1|hsa-mir-527|hsa-mir-516a-1|hsa-mir-516a-2|hsa-mir-519a-2|hsa-mir-
1323|hsa-mir-1283-1|hsa-mir-1283-2  
2 
hsa-mir-134|hsa-mir-154|hsa-mir-299|hsa-mir-376c|hsa-mir-369|hsa-mir-
376a-1|hsa-mir-377|hsa-mir-379|hsa-mir-380|hsa-mir-381|hsa-mir-382|hsa-
mir-323|hsa-mir-329-1|hsa-mir-329-2|hsa-mir-453|hsa-mir-409|hsa-mir-
412|hsa-mir-410|hsa-mir-376b|hsa-mir-485|hsa-mir-487a|hsa-mir-494|hsa-
mir-495|hsa-mir-496|hsa-mir-539|hsa-mir-544|hsa-mir-376a-2|hsa-mir-
487b|hsa-mir-411|hsa-mir-654|hsa-mir-655|hsa-mir-656|hsa-mir-758|hsa-
mir-668|hsa-mir-1185-2|hsa-mir-1185-1|hsa-mir-300|hsa-mir-541|hsa-mir-
889|hsa-mir-543|hsa-mir-1197  
3 hsa-mir-16-2|hsa-mir-15b  
4 hsa-mir-105-1|hsa-mir-105-2|hsa-mir-767  
5 hsa-mir-127|hsa-mir-136|hsa-mir-370|hsa-mir-337|hsa-mir-431|hsa-mir-433|hsa-mir-493|hsa-mir-432|hsa-mir-770|hsa-mir-665  
6 hsa-mir-34b|hsa-mir-34c  
7 hsa-mir-144|hsa-mir-451  
8 hsa-mir-365-1|hsa-mir-193b  
9 hsa-mir-224|hsa-mir-452  
10 hsa-mir-421|hsa-mir-374b  
11 hsa-mir-449a|hsa-mir-449b  
12 hsa-mir-296|hsa-mir-298  
13 hsa-mir-424|hsa-mir-450a-1|hsa-mir-450a-2|hsa-mir-503|hsa-mir-542|hsa-
mir-450b  
14 hsa-mir-215|hsa-mir-194-1  
15 hsa-mir-221|hsa-mir-222  
16 hsa-mir-141|hsa-mir-200c  
17 hsa-let-7c|hsa-mir-99a  
18 hsa-mir-195|hsa-mir-497  
19 hsa-mir-143|hsa-mir-145  
20 hsa-mir-23a|hsa-mir-24-2|hsa-mir-27a  
21 hsa-let-7g|hsa-mir-135a-1  
22 hsa-mir-181b-1|hsa-mir-181a-1  
23 hsa-let-7a-3|hsa-let-7b  
24 hsa-let-7a-2|hsa-mir-100|hsa-mir-125b-1  
25 hsa-mir-25|hsa-mir-93|hsa-mir-106b  
26 hsa-mir-24-1|hsa-mir-23b|hsa-mir-27b  
27 hsa-mir-181c|hsa-mir-181d  
28 hsa-mir-191|hsa-mir-425  
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29 hsa-mir-30c-1|hsa-mir-30e  
30 hsa-let-7a-1|hsa-let-7d|hsa-let-7f-1  
31 hsa-mir-193a|hsa-mir-365-2  
32 hsa-mir-30a|hsa-mir-30c-2  
33 hsa-mir-15a|hsa-mir-16-1  
34 hsa-mir-19b-2|hsa-mir-92a-2|hsa-mir-106a|hsa-mir-363|hsa-mir-18b|hsa-
mir-20b  
35 hsa-mir-302a|hsa-mir-302b|hsa-mir-302c|hsa-mir-302d|hsa-mir-367  
36 hsa-mir-216a|hsa-mir-217|hsa-mir-216b  
37 hsa-mir-29a|hsa-mir-29b-1  
38 hsa-mir-212|hsa-mir-132  
39 hsa-mir-199a-2|hsa-mir-214  
40 hsa-mir-29b-2|hsa-mir-29c  
41 hsa-mir-188|hsa-mir-362|hsa-mir-500|hsa-mir-501|hsa-mir-502|hsa-mir-532|hsa-mir-660  
42 hsa-let-7e|hsa-mir-125a|hsa-mir-99b  
43 hsa-mir-1-2|hsa-mir-133a-1  
44 hsa-mir-200b|hsa-mir-200a|hsa-mir-429  
45 hsa-mir-192|hsa-mir-194-2  
46 hsa-mir-17|hsa-mir-18a|hsa-mir-19a|hsa-mir-19b-1|hsa-mir-20a|hsa-mir-92a-1  
47 hsa-mir-96|hsa-mir-182|hsa-mir-183  
48 hsa-mir-30d|hsa-mir-30b  
49 hsa-mir-133a-2|hsa-mir-1-1  
50 hsa-mir-181a-2|hsa-mir-181b-2  
51 hsa-mir-206|hsa-mir-133b  
52 hsa-let-7f-2|hsa-mir-98  
 
  
55 
 
 For the strong assumption regarding as the log-normality and equal variance for 
PASM we performed a normalization based on z-score transformation in R. The 
P-values were calculated against 1000 randomized samples. 
 
6. Cell culture and miRNAs transfection 
MDA-MB-231, MCF7 and UACC-257 were cultured in liquid culture with 
Dulbecco’s modified eagle medium (DMEM; GIBCO Laboratories, Grand Island, 
NY, USA) and RPMI supplemented with heat-inactivated 10% fetal bovine serum 
(FBS; Equitech-Bio, Kerrville, TX, USA) and a 1% antibiotic antimycotic solution 
(Invitrogen, CA, USA). The cells were maintained at 37°C in a humidified 
atmosphere with 5% CO2. Mature microRNAs mimics from miR-500 were 
purchased from Ambion Inc.  To estimate transfection efficiency, the negative 
control FAM (carboxyfluorescein) labeled RNA oligonucleotide (Ambion, TX, USA) 
were used. The oligonucleotides were individually transfected with 
Oligofectamine reagent (Invitrogen, CA, USA) at the final concentration of 100 
pmol/well for a 12-well plate. After 48-h post-transfection, cells were harvested 
and analyzed. 
 
7. Microarray and data analysis 
Two breast cancer cell lines (MDA-MB-231 and MCF7) were used for analysis of 
gene expression data after transfecting miR-500 mimic (Ambion, TX, USA) and 
control. Total RNA was extracted by using the mirVana miRNA Isolation kit 
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(Ambion, TX, USA). 750 ng of total RNA was used for labeling. Sample labeling 
was performed with an RNA amplification kit according to the manufacturer’s 
instructions (Applied Biosystems; Foster City, CA). We used the HumanHT-12 v4 
expression beadchip containing 48000 probes of 25000 annotated genes from 
Illumina Inc (San Diego, CA). After hybridization according to the manufacturer’s 
protocols (Illumina®), the bead chip was scanned with a BeadArray Reader 
(Illumina®) and microarray data were log2-transformed and normalized using the 
quantile normalization method in the Linear Models for Microarray Data package 
in Bioconductor.  Primary microarray data are available in the National Center for 
Biotechnology Information Gene Expression Omnibus public database 
(GSE61752). BRB-ArrayTools were used for statistical analysis of gene 
expression data (Simon et al. 2007). For class comparison between control and 
test samples treated by miR-500, the t-test was applied to identify the genes 
significantly different between two groups when compared using BRB ArrayTools 
(Qi et al. 2009). Gene expression differences were considered significant if P < 
0.001. Cluster analysis was performed using the software programs Cluster and 
Heatmap was generated by Treeview (Eisen et al. 1998).   
 
8. 3’-UTR luciferase reporter assays 
To evaluate miR-500 binding to the PPFIA1 3′-UTR, 74-bp oligonucleotides 
spanning the predicted 3′-UTR miRNA binding site flanked by XhoI and NotI 
restriction sites were cloned into pmirGLO Dual-Luciferase miRNA target 
Expression vector (Promega). Oligonucleotides with a mutated binding site were 
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used as control. Breast cancer and melanoma cells were seeded at a density of 
10,000 cells per well in an opaque 6-well plate. Twenty-four hours after seeding, 
cells were co-transfected with a miR-500 pre-miR (Ambion) or negative control 
pre-miR (Ambion) in combination with the vectors. Forty-eight hours after 
transfection, luciferase reporter gene activity was measured using the Dual-Glo 
Luciferase Assay System (Promega) and a FLUOstar OPTIMA microplate reader 
(BMG LABTECH). 
 
9. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich) assay was performed as described previously (Mosmann 1983) to 
assess cell proliferation after mimic miR-500 treatment or control in MDA-MB-231 
cells. Cells were plated into 12-well plates, transfected with mimic and control 
and incubated for 48 hrs. Cells were fixed in 10% formaldehyde and stained in 10% 
Crystal violet (Sigma-Aldrich) for 10 min at room temperature. The absorbance of 
individual wells was read using by a VMax kinetic microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) at 570nm. 
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10. shRNAs and lentiviral transduction. 
 
Letiviral-based shRNA against human (Sigma-Aldrich, St. Louis, MO,), human 
PPP2R5E and PPFIA1, and control shRNA targeting eGFP (Cat. No. SHC005V) 
were used for knock-down experiments. Lentivirus particles were produced by 
transient transfection of shRNA expression vectors along with packaging vectors 
pLP1, pLP2, and pLP/VSVG (Invitrogen, Carlsbad, CA) in 293FT cells. The 
lentiviral supernatants were collected at 48-72 hours post transfection and frozen 
in aliquots. A moderate multiplicity of infection (MOI=3) was used for transduction 
of cells to minimize negative effects on cellular proliferation. At 2 to 4 days after 
infection, all experiments were performed. Reverse transcription polymerase 
chain reaction (RT-PCR) was performed to quantify the mRNA of PPP2R5E and 
PPFIA1 to examine the knock-down efficiency with the primers (Table 10).  
 
Table 10. Primers for qRT-PCR 
Gene Forward Reverse 
PPFIA1 CCACATCTGTGCATGACCTC TTCCAAGCGCTCCTGTAACT 
PPP2R5E GTATGTGGCTGTCAGCTCGT TTGTGGCGTTGGTGTACAAT 
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11.      Western blot analysis 
 
The culture cell samples were homogenized at 4°C in a protein lysis buffer. Equal 
amounts of total protein from each sample were resolved through a 10% SDS–
PAGE gel and then transferred to a PVDF membrane (Perkin Elmer Life 
Scientific Inc.). The membranes were blocked with 5% non-fat dried skimmed 
milk powder solution for 1 h, and then incubated overnight at 4◦C with 
monoclonal or polyclonal antibodies for Phospho-MAP2K1 (Ser217/221, 1:1000, 
Cell Signaling Technology), MAP2K1 (1:1000, Cell Signaling Technology), and α-
tublin (1:1000, Cell Signaling Technology). After washing with TBST (Tris-
buffered saline with Tween; 20 mM Tris/HCl, pH 7.6, 150 mM NaCl and 0.05% 
Tween 20), the membranes were incubated with a secondary antibody against 
rabbit or mouse IgG. Then the membranes were washed, and protein was 
detected with an ECL (enhanced chemiluminescence) kit (Bio-Rad). 
 
12. Database implementation 
We implemented a web-based miRNA-RPPA-pathway profiling system (miRPP, 
http://www.appex.kr/mirpp) based on our approach using a host language, JAVA 
(http://www.java.com). To provide user friendly and active interfaces, Google web 
toolkit (GWT, http://www.gwtproject.org/) and GWT extended (GXT, 
http://www.sencha.com/products/gxt) frameworks were used. The data 
transporting between client and miRPP server is controlled by GWT remote 
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procedure call (RPC) method. All statistical analysis methods of miRPP were 
implemented by R script language (http://www.r-project.org) with Bioconductor 
plugins (http://www.bioconductor.org). Calling R modules from a host language is 
managed by RCaller framework (https://code.google.com/p/rcaller). To store and 
handle the association scores and expression intensities, MySQL database 
management system was applied (http://dev.mysql.com). In addition, data query 
on MySQL from a host language is controlled by MyBatis, a XML based SQL 
mapping framework (https://code.google.com/p/mybatis). All services of miRPP 
are contained and served on an Apache Tomcat web server 
(http://tomcat.apache.org). 
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CHAPTER 3 
CONSTRUCTION OF CORRELATION MATRIX OF MICRORNAS, 
MRNA, AND PROTEIN FEATURES IN NCI-60 CELL LINES. 
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1. Microarray Expression data sets 
 
In this study, we used three different level of data sets in NCI-60 cells as the 
followings: mRNA array (45k probes), miRNA array (439 probes), RPPA (222 
probes). Figure.15 shows the overall expression pattern of each data set. We 
found the tissue specific signature of human tumors in the clustering analysis. 
For example, in the clustering of miRNA expression data we found the 
expression signatures depending on tumor types which were reported in the 
previous study (Olive et al. 2010) (Fig15C.).  
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Figure 15. Overall expression pattern of omics data sets in NCI-60 cells. (A) 
mRNA array data, (B) miRNA array data, (C) RPPA data (Park et al. 2010). After 
variance filtering of probes with low standard deviation in mRNA data set, 
hierarchical clustering was performed. MicroRNA and RPPA data were clustered 
with all probes. 
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2. Construction of correlation matrix of miRNAs, mRNA, and protein 
features in NCI-60 cell lines.  
 
For the development of algorithms, we selected data sets of miRNAs, mRNAs, 
and protein expression from NCI-60 cell lines rather than from other data sets 
because NCI-60 cell lines are the most extensively characterized lines (Bussey 
et al. 2006; Liu et al. 2010b; Zeeberg et al. 2012; Varma et al. 2014), and 
although data size is relatively small but they represent major tumor types well. 
More importantly, these cell lines can be quickly tested for validation of molecular 
functions predicted by algorithms.   
A schematic overview of our approach is shown in Figure.16. Because 
miRNAs indirectly regulate expression and activation of proteins through 
targeting mRNAs, we tried to develop an analysis approach that would mimic 
biological process of regulatory circuits in cells.  
In the correlation analysis between miRNA and mRNA data sets we found 
that top ranked miRNAs by the number of correlated mRNAs tends to be more 
tumor specific. For example, among these miRNAs in Table.11  the previous 
study showed that mir-093-prec and mir-106, mir-107, mir-020, mir-099, and mir-
017 were differentially expressed in tumors compared with non-tumorous tissues 
(Paranjape et al. 2009).  
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Figure 16. Schematic overview illustrating data analysis process. Data 
analysis was carried out in three steps. In first step, two correlation matrices 
(miRNAs vs. mRNAs, and mRNAs vs. protein features) were generated by using 
Pearson correlation values. Two correlation matrices were integrated later by 
using mRNAs as denominators, generating association score between miRNAs 
and protein features. Resulted association scores represent number of 
commonly correlated mRNAs between miRNAs and protein features in matrix 
format. In second step, the P/U ratios (number of mRNAs associated with 
phosphorylated protein/number of mRNAs associated with unmodified protein) of 
each miRNA are mapped into signaling pathways and used to generate Pathway 
Association Score (PAS). PAS is later was normalized through z-score 
transformation with 1000 permutation. In last step, miRNA cluster enrichment 
analysis over signaling pathways was carried out with PASM and miRNA cluster 
information.  
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Table 11. Top 20 miRNA ranked by the number of correlated mRNAs 
 
miRNA # of correlated mRNA probes(%)* 
mir-093-prec-7.1=093-1 1841(8.07) 
mir-106bNo1 1579(6.92) 
mir-125b-2-precNo2 1424(6.24) 
mir-106-prec-X 1357(5.95) 
mir-142-prec 1337(5.86) 
mir-125b-1 1327(5.82) 
mir-020-prec 1268(5.56) 
mir-106aNo1 1217(5.34) 
mir-100No1 1216(5.33) 
mir-025-prec 1208(5.3) 
mir-509No1 1180(5.17) 
mir-032-precNo2 1168(5.12) 
mir-20bNo1 1138(4.99) 
mir-099-prec-21 1117(4.9) 
mir-200cNo1 1099(4.82) 
mir-125a-precNo1 1065(4.67) 
mir-023a-prec 1053(4.62) 
mir-018-prec 1042(4.57) 
mir-017-precNo2 1021(4.48) 
mir-513-2No1 1018(4.46) 
*p-val < 0.005 
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First, we generated a correlation matrix between expression of miRNAs and 
mRNAs by using expression data from NCI-60 cell lines (Liu et al. 2010b); 
302,712 pairs were significantly correlated (P < 0.005).  Second, we generated a 
correlation matrix between expression of mRNAs and protein features 
(expression and phosphorylation) (Zeeberg et al. 2012; Varma et al. 2014) two 
correlation matrices were integrated together by using mRNAs as denominators 
connecting miRNAs to protein features, reflecting indirect regulation of proteins 
by miRNAs. Briefly, significantly correlated mRNAs for a particular miRNA were 
cross-compared with significantly correlated mRNAs for all proteins to generate 
association scores of the miRNA across all proteins. Thus, association scores 
represent number of commonly correlated mRNAs between miRNAs and protein 
features in matrix format (Fig. 17).  
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Figure 17. Schematic overview illustrating data integration. Pearson's 
correlation coefficient analysis was performed to generate two correlated pair 
sets; miRNA-mRNA and RPPA-mRNA pairs. In correlation analysis, P-value less 
than 0.005 was considered to be statistically significant. To establish the 
association between miRNA and protein, two independently generated  
correlation matrices were integrated by counting correlated mRNAs as 
denominators. Association score represents the log2 transformed number of 
commonly correlated mRNAs with the both miRNA and RPPA probe. 
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To explore the distribution of ASM we made a density plot with all association 
scores between miRNAs and RPPA proteins. It showed a Gaussian distribution 
over 2 (Fig.18). When using ASM integrated together by counting correlated 
mRNAs between miRNA and RPPA (cut-off >7), we found one of miRNA clusters 
representing miR-200 cluster (Fig.19).  This cluster showed the high association 
with E-cadherin, AKT, PI3K and other proteins. The previous studies showed 
MiR-200 family play important role in EMT pathway including E-cadherin and 
also in AKT pathway (Cancer Genome Atlas Research 2014).   
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Figure 18. Density plot of Association scores. X-axis represents log2 based 
values. The table shows the number of significantly correlated miRNA-RPPA 
pairs depending on the cut-off. 
 
 
  
Figure 19 . miR-200 cluster associated with RPPA proteins in ASM
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CHAPTER 4 
F MICRORNAS IN SIGNALING 
PATHWAYS 
.   
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Signaling events of pathways are best reflected in modification of signaling 
proteins such as for phosphorylation (Karin and Hunter 1995). RPPA has been 
used for the comprehensive analysis of protein expression levels and activation 
status in signaling pathways through measuring phosphorylation status of gene 
products (Tibes et al. 2006). Using information from antibody pairs that can 
recognize unmodified form or phosphorylated form of the same protein, we 
assessed the significance of phosphorylation by identifying the number of genes 
whose expression patterns are significantly correlated with the degree of 
phosphorylation over expression of the protein. 
Because signaling events of pathways are best reflected in modification of 
signaling proteins like phosphorylation and vast majority of downstream effectors 
of many signaling pathways are transcription regulators, we hypothesize that 
cellular signaling activity would be well reflected in number of mRNAs whose 
expression patterns are correlated with signaling events like phosphorylation of 
signaling proteins. Therefore, we tried to estimate signaling activities in NCI-60 
cells by computing correlated number of mRNAs with phosphorylation of 
signaling proteins. RPPA used 25 antibody pairs that recognize unmodified or 
phosphorylated form of signaling proteins (Table 1). By selecting out 25 pairs of 
correlation data between mRNAs and protein features from correlation matrix, we 
generated P/U ratios (number of mRNAs associated with phosphorylated 
protein/number of mRNAs associated with unmodified protein) as indicator of 
signaling activity of signaling proteins in NCI-60 cell lines.   
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To correlate miRNAs to signaling activity of 25 signaling proteins, we next 
generated matrix between miRNAs and P/U ratios of each proteins (436 miRNAs 
x 25 P/U ratios of signaling proteins) by using association scores in ASM from 
previous analysis. Because 25 signaling proteins are involved in regulation of 40 
signaling pathways (Table 12), we computed the sum of P/U ratios of the 
proteins in each signaling pathway per each miRNA, generating Pathway 
Association Score (PAS) that well reflected the association of miRNAs to 
signaling pathways and the matrix of PAS (PASM). Significance of miRNAs 
associated with signaling pathways was estimated by enrichment analysis using 
association values in PASM and miRNA genome cluster information because 
miRNAs in the same genomic cluster share target mRNAs and biological function 
(Gurtan and Sharp 2013).  This analysis yielded functionally matched list 
between signaling pathways and miRNA clusters (Table 3). Some mRNA 
clusters seem to be involved in regulation of many signaling pathways. For 
example, miRNAs in cluster 5 (hsa-mir-127, -136, -370, -337, -431, -433, -493, -
432, -770 and  -665 ) showed frequent association with multiple signaling 
pathways. Interestingly, substantial fraction of signaling pathways associated 
with cluster 5 is immune-response pathways, suggesting that miRNAs in cluster 
5 might be important regulators of immune systems.   For instance, a previous 
study reported that hsa-miR-127 is involved in B-cell differentiation process 
(Leucci et al. 2010). 
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Table 12.  MicroRNA cluster enriched pathway 
Pathway DB Cluster COUNT Z-SCORE 
P-
VALUE 
q-
VALUE 
PELP1 pathway  BIOCARTA 35 14 4.03653 5.43E-05 0.000762 
FC EPSILON RI signaling pathway  KEGG 5 14 3.55105 0.000384 0.01867 
T-CELL RECEPTOR signaling pathway  KEGG 5 14 3.55105 0.000384 0.01867 
CREB pathway   BIOCARTA 5 14 3.52968 0.000416 0.018861 
BIOPEPTIDES pathway   BIOCARTA 5 14 3.48198 0.000498 0.015912 
ADIPOCYTOKINE signaling pathway  KEGG 46 7 3.31242 0.000925 0.028157 
HCMV pathway   BIOCARTA 5 14 3.26827 0.001082 0.0326 
TOLL LIKE RECEPTOR signaling pathway  KEGG 5 14 3.26827 0.001082 0.0326 
CHEMOKINE signaling pathway  KEGG 5 14 3.26103 0.00111 0.02751 
ERK pathway   BIOCARTA 41 9 3.21621 0.001299 0.050206 
NFAT pathway   BIOCARTA 5 14 3.1846 0.00145 0.043812 
PROGESTERONE MEDIATED OOCYTE 
MATURATION  
KEGG 
5 14 
3.13745 0.001704 0.053421 
BIOPEPTIDES pathway   BIOCARTA 2 38 3.07015 0.002139 0.034201 
FC GAMMA R MEDIATED 
PHAGOCYTOSIS  
KEGG 
5 14 
3.05116 0.00228 0.080329 
NEUROTROPHIN signaling pathway  KEGG 5 14 2.99409 0.002753 0.142044 
HER2 pathway  BIOCARTA 41 9 2.90519 0.00367 0.041129 
MTOR pathway   BIOCARTA 47 6 2.90323 0.003693 0.034864 
TPO pathway   BIOCARTA 4 3 2.89114 0.003838 0.199599 
PDGF pathway   BIOCARTA 4 3 2.89114 0.003838 0.199599 
EGF pathway   BIOCARTA 4 3 2.89114 0.003838 0.199599 
IL4 pathway  BIOCARTA 7 3 2.83008 0.004654 0.030358 
EIF4 pathway  BIOCARTA 5 14 2.81424 0.004889 0.12102 
ADIPOCYTOKINE signaling pathway  KEGG 26 4 2.80944 0.004963 0.053712 
VEGF signaling pathway  KEGG 5 14 2.80882 0.004972 0.053927 
VEGF signaling pathway  KEGG 23 2 2.69258 0.00709 0.053927 
EDG1 pathway  BIOCARTA 5 14 2.67643 0.007441 0.172658 
MAPK signaling pathway  KEGG 5 14 2.63849 0.008328 0.216517 
ERK pathway   BIOCARTA 4 3 2.58685 0.009686 0.187181 
CHEMOKINE signaling pathway  KEGG 23 2 2.52562 0.01155 0.090542 
IGF1R pathway  BIOCARTA 5 14 2.52197 0.01167 0.219031 
 
Top 30 overrepresented pathways with p < 0.02  The pathway and cluster are sorted by 
p-value of Parametric gene set enrichment analysis 
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1.  Web-based Database system, miRPP 
 
Based on our approach we implemented a web-based tool, miRNA-RPPA-
pathway profiling system (miRPP) (Fig.20). miRPP provides the following 
information against a query miRNA in NCI-60 data sets: Overall expression of 
significantly correlated mRNAs and RPPA protein probes, mRNA mediated 
Association Score Matrix between miRNAs and RPPA probes, and miRNA 
associated cell signaling pathways. 
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Figure 20 . miRNA-RPPA-Pathway Association Profiler (miRPP). miRPP 
provides the following information against a miRNA in NCI-60 data sets: Overall 
expression of significantly correlated mRNAs and RPPA protein probes, mRNA 
mediated Association Score Matrix between miRNAs and RPPA probes, and 
miRNA associated cell signaling pathways. It was implemented by JAVA. For 
user friendly and active interfaces, Google web toolkit (GWT) and GWT extended 
(GXT) frameworks were used. RPPA: Reverse phase protein array. 
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2.  Biological and clinical significance of miR-500 
 
Because MAPK pathway is critical for regulation of cell growth and cross-talk with 
many other signaling pathways (De Luca et al. 2012; Deschenes-Simard et al. 
2014), we selected miRNAs (cluster 41; hsa-mir-188, -362, -500, -501, -502, -532, 
and -660) significantly associated with MAPK pathway for further functional 
validation (Table.13). We found strong association between miR-500 cluster and 
proteins in MAPK pathway (Fig.21). Out of 7 miRNAs in cluster 41, we further 
selected miR-500 because its expression was most significantly associated with 
activation of MAPK pathway as judged by correlation between its expression and 
phosphorylation of MAP2K1, a key upstream regulator of MAPK1 (Sebolt-
Leopold 2000; Chowdhury et al. 2014; Neuzillet et al. 2014). We also found that 
MAP2K1 had high score of P/U ratio against miR-500 (Fig. 22). Among miR-500 
cluster members, the phosphorylation of MAP2K1 was significantly correlated 
with miR-500 expression in NCI-60 cells (Fig.23). 
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Table 13. Hsa-mir-500 information from miRBase* 
Accession MI0003184 
Previous IDs hsa-mir-500 
Symbol HGNC:MIR500 
Description Homo sapiens miR-500a stem-loop 
Gene family MIPF0000139; mir-500 
Genome context Coordinates (GRCh38) chrX: 50008431-50008514 [+] 
Stem-loop 
 c c     -u         uac ug    agag   ugu  
gcuc c cucuc  aauccuugc   c  ggug    ugc   c 
|||| | |||||  |||||||||   |  ||||    |||   u 
cgag g gagag  uuaggaacg   g  ccac    acg   g 
    a c     uc         --- gu    -gua   uaa 
Clustered miRNAs 
< 10kb from hsa-mir-500a > 
hsa-mir-532 chrX: 50003148-50003238 [+]  
hsa-mir-188 chrX: 50003503-50003588 [+]  
hsa-mir-500a chrX: 50008431-50008514 [+]  
hsa-mir-362 chrX: 50008964-50009028 [+]  
hsa-mir-501 chrX: 50009722-50009805 [+]  
hsa-mir-500b chrX: 50010672-50010750 [+]  
hsa-mir-660 chrX: 50013241-50013337 [+]  
hsa-mir-502 chrX: 50014598-50014683 [+]  
 
*http://www.mirbase.org 
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Figure 21.  Association between miR-500s and the proteins in MAPK 
pathway. (A) Heatmap of ASM against miR-500s. (B) Direct correlation of 
expression data between miR-500s and proteins in MAPK pathway. MEK1/2 
(official symbol: MAP2K1) 
 
A 
B 
  
 
 
 
Figure 22. P/U ratio of the protein pairs against miR
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 Figure 23. Association between miRNAs in cluster 41 and 
of MAP2K1in NCI-60 cells.
correlation matrix between miRNAs in cluster 41 and phosphorylation level of 
MAP2K1 in NCI-60 cells. Numbers in boxes represent correlation and size of 
number reflect strength of correlation. pMAP2K1, Phosphorylated MAP2K1. 
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phosphorylation 
 Pearson correlation approach was used to generate 
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3. Chloride channel protein 5 (CLCN5) 
 
CLCN5 gene is a member of the CIC family of chloride ion channels and ion 
transports. It is localized to endosomal membranes. Its mutations induce Dent 
disease and renal tubular disorders complicnephrolithiasis, and functions as 
antiport system and exchanges chloride ions against protons (Akbani et al. 2014). 
CLCN5 also is localized in Golgi apparatus membrane (http://www.genecards.org) 
and highly expressed in Kidney tissue, moderately in aortic vascular smooth 
muscle and endothelial cells, and a little higher in the coronary vascular smooth 
muscle (Fig.24). 
 
 
 
 
Figure 24. mRNA expression of CLCN5 in nomal and cancer tissues  
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Interestingly, expression of miR-500 is significantly higher in melanoma and 
breast cancer cell lines (Fig. 25A), suggesting potential roles of miR-500 in 
regulation of MAPK pathway in these cancer types. Since miRNA cluster 41 is 
co-localized with CLCN5 gene and expressed as part of CLCN5 transcript, we 
assessed correlation of expression of miRNAs in cluster 41 and CLCN5 in NCI-
60 cell lines (Fig. 25B). Interestingly, correlation was highest between miR-500 
and CLCN5.  Because expression of CLCN5 is highly correlated with expression 
of miR-500, we next assessed potential clinical relevance of miR-500 in 
melanoma by using mRNA expression data of tumor tissues from patients with 
melanoma (GSE19234) (Lorenzi et al. 2009). When patients were dichotomized 
according to expression of CLCN5, high expression of CLCN5 was significantly 
associated with shorter overall survival (Fig. 25C), strongly suggesting that miR-
500 might play roles as oncogene presumably by activating MAPK pathway in 
melanoma. 
  
  
 
 
 
 
Figure 25. miR-500 is significantly associated with prognosis of patients 
with melanoma. (A) Average expression of miRNAs in cluster 41 in NCI
lines. Among 7 miRNAs in cluster 41, probes for 5 miRNAs were available in 
expression data. The expression values are normalized and averaged in each 
tissue. (B) Correlation analysis between mi
expression of CLCN5 
survival of patients dichotomized according to the expression of 
86 
RNAs in cluster 41 and the mRNA 
in NCI-60 cell lines.  (C) Kaplan-Meier plots of overall 
CLCN5
-60 cell 
. 
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CHAPTER 5 
IN-VITRO VALIDATION OF PREDICTED TARGETS OF MIR-500 
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1. Hypothesis and experimental design 
 
In-silico analysis we identified that miR-500 expression is significantly associated 
with MAPK pathway and positively correlated with the phosphorylation of 
MAP2K1. Therefore, we hypotheses when miR-500 mimic is treated into cells the 
phosphorylation level of MAP2K1 will be increased (Fig.26). 
 
 
 
 
 
Figure 26. Experimental design to examine the increase of MAP2K1 
phosphorylation by miR-500 in melanoma and breast cancer cells. 
- Control 
- Mimic miR-500  
 
Phosphorylation level of MAP2K1 (S217.S221) ?  
MB231, MCF7 or UACC257 
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2. Screening direct targets of miR-500 through In-vitro assays  
 
Because our analysis suggested significant correlation of miR-500 with MAPK 
pathway, we hypothesized that miR-500 regulates MAP2K1 in melanoma cells. 
To do this, we transfected miR-500 mimic into UACC-257 melanoma cell and 
measured phosphorylation of MAP2K1, reflecting activation of MAP2K1 
(Mammano et al. 2012; Federici et al. 2013) (Fig.27).  In good agreement with 
our hypothesis, MAP2K1 was activated upon transfection of miR-500 mimic as 
evidenced by increased phosphorylation of MAP2K1 (Fig. 28A). To verify that 
the effect was not specific to melanoma cells and was occurred independently of 
BRAF mutation status, we further tested the ability of miR-500 to activate 
MAP2K1 in two MCF7 and MDA-MB-231 breast cancer cell lines. MCF7 cells do 
not have BRAF mutation. Consistent with result from UACC-257, we observed 
activation of MAP2K1 when miR-500 mimic were transfected into MCF7 and 
MDA-MB-231 cells, strongly suggesting that miR-500 regulates MAPK pathway 
by activating MAP2K1. In addition, cell growth was significantly increased upon 
introduction of miR-500 mimic to MDA-MB-231 cells (Fig. 28B), further 
supporting that MAPK pathway is really activated.  
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Figure 27.  Representative photographs of Negative control miRNA with 
FAMTM. Control miRNAs were transfected under light (left), epifluorescence (mid), 
overlay (right) microscopy in MB-231, UACC-257 and MCF7 cells.   
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Figure 28. miR-500 regulates phosphorylation of MAP2K1. (A) Western blots 
for expression and phosphorylation of MAP2K1 in miR-500 transfected 
melanoma and breast cancer cells.  α-Tubulin was used as loading control. (B) 
miR-500 significantly increased proliferation of MDA-MB-231 cells. MTT 
proliferation assay was carried out 48 hours after treating cells with miR-500 
mimic or control (P < 0.01 by Student t-test).   
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To determine the molecular mechanism by which miR-500 regulates MAP2K1, 
we performed microarray experiments after transfecting miR-500 mimic into 
MCF7 and MDA-MB-231 breast cancer cells. Because MAPK pathway can be 
activated in UACC-257 melanoma cells with a BRAF mutation, we used breast 
cancer cells to identify more direct downstream effect on the MAP2K1 
phosphorylation by miR-500. Then microarray experiment was performed with 
extracted RNA. 
Analysis of gene expression data revealed that expression of 719 genes 
was significantly changed in both cell lines (P < 0.001, Two sample t-test). 
Because miRNAs negatively regulates mRNAs by directly targeting them, we 
further selected genes whose expression is commonly down-regulated by miR-
500 (Fig. 29). Of 719 genes, 447 genes were commonly downregulated by miR-
500 in the both cells. Because miR-500 activated MAP2K1 while miRNAs 
negatively regulates their targets, we reasoned that targets of miR-500 for 
regulation of MAP2K1 might be negative regulators of MAP2K1. Phosphatases 
are best known negative regulators of kinase-mediated signaling pathways 
(Roskoski 2012).  Therefore, we further selected mRNAs of phosphatase families 
with predicted target sequence of miR-500 as candidates for key regulators by 
using starBase database providing miRNA-target interactions (Yang et al. 2011; 
Chou et al. 2013). There are only two phosphatases or its binding proteins 
(PPP2R5E and PPFIA1) with target sequence of miR-500 among down-
regulated genes by miR-500.  We performed the protein-protein interaction 
 network analysis related to two putative targets with STRING
(Fig.30 ). 
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 (http://string-db.org)  
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Figure 29. Gene expression of MDA-MB-231 and MCF7 cells after the 
transfection of mimic miR-500 or control. Gene expression was used for 
hierarchical clustering after filtering genes with low SD. The data were 
centralized by subtracting median expression level across samples for clustering 
analysis. 3047 genes were presented in the data set. The data are presented in 
matrix format in which rows represent individual gene and columns represent 
each sample. Each cell in the matrix represents the expression level of a gene 
feature in an individual sample. The red and green color in cells reflect relative 
high and low expression levels respectively as indicated in the scale bar (log2 
transformed scale).   
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Figure 30. Protein-Protein Interaction network(PPI) of  phosphatase associated 
proteins from the microarray data analysis. STRING is the database for Known 
and predicted protein-protein interactions. 
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To test if they are involved in regulation of MAP2K1, we silenced their expression 
in MCF7 and UACC-257 cells and measured phosphorylation of MAP2K1. 
Silencing of PPFIA1 activated MAP2K1 in both cell lines whereas silencing of 
PPP2R5E had no effect on MAP2K1 activity (Fig. 31B), suggesting that PPFIA1 
might be negative regulator that is regulated by miR-500 for activation of MAPK 
pathway.  To determine whether miR-500 directly targets the 3’UTR of PPFIA1 
mRNA, we used a luciferase reporter vector containing the 3’UTR sequence of 
PPFIA1, including the predicted binding site for miR-500 in UACC-257 cells. 
Luciferase activity was significantly inhibited by the PPFIA1 3’UTR sequence 
when only miR-500 were co-transfected (Fig. 31D). However, luciferase activity 
was not inhibited by a mutant 3’UTR sequence (Fig. 31C and 31D), strongly 
demonstrating that miR-500 directly targets the 3’UTR sequence of PPFIA1 
mRNA and inhibits the expression of PPFIA1. 
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Figure 31. PPFIA as a direct target of miR-500 for regulation of MAP2K1. (A) 
Commonly down-regulated genes in MB-231 and MCF7 cells. After transfecting 
mimic miR-500 and control in MB-231 and MCF7 cells whole genome microarray 
experiment was performed and differentially expressed genes in two cell lines 
were selected by two-sample t-test (P < 0.001). (B) Western blots for 
phosphorylation of MAP2K1 after silencing PPFIA1 and PPP2R5E in UACC-527 
and MCG7 cells. Cells were transfected with specific shRNAs for 72 hrs. α-
Tubulin was used as a loading control. (C) The miR-500 binding site in the 3′-
UTR of PPFIA1 mRNA.(D) Luciferase reporter assays used vectors including WT 
or Mutant sequences against 3’-UTR region of PPFIA1.  
 
  
99 
 
 
CHAPTER 6 
DISCUSSION  
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MicroRNAs have critical roles as a main regulator in post transcriptional level. 
Because miRNAs have small nucleotide sequences, it is challengeable to 
characterize their functional roles in abnormal signaling pathways in cancer. In 
this study we developed a new correlation based approach on the integration of 
the three levels of omics data including miRNA, mRNA, and protein array data, 
for miRNA targeted biological pathways. In this approach we generated ASM and 
PASM for predict miRNA associated pathways. To validate our prediction that 
miR-500 is associated with MAPK pathway, we performed in-vitro experiment 
and found that miR-500 increased the phosphorylation of MAP2K1 by regulating 
PPFIA1 as a direct miR-500 target in melanoma and breast cancer cells. 
 
Using three independent data sets (miRNAs, mRNAs, and proteins) from NCI-60 
cell lines, we developed a series of systematic integration methods that can 
uncover functional roles of miRNAs in regulation of signaling pathways important 
for cancer development and established functional connection map of miRNAs to 
signaling pathways.  
 
Our approaches have several advantages over conventional approaches.  First, 
our analytical approach mimics natural process of cellular regulation in which 
miRNAs target mRNAs to regulate protein expression.  We estimated the 
functional association between miRNAs and proteins by using mRNAs as 
intermediate denominators that were used to establish the functional connection 
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of miRNAs to signaling pathways.  In our approach these intermediate 
denominators might contribute to reflecting biological context for identifying 
miRNA function in signaling pathway. Second, because miRNAs are connected 
to signaling pathways that are a functional unit of cellular regulation, 
interpretation of the data is easier and straightforward. Third, because we used 
data from NCI-60 cell lines that have been extensively characterized, the 
identified functional association can be easily tested and validated in cell lines as 
demonstrated in current study. Lastly, in our study we estimated the function of 
miRNA clusters in signaling pathways in cancer.  Such clusters would more 
reliably predict the association between miRNAs and signaling pathways 
compared with using a single miRNA to understand their function and 
mechanism in various biological processes, because miRNAs in the same cluster 
are frequently regulated together.  
 
While our approach uncovered new functional connections of miRNAs to 
signaling pathways, some of identified functional connection of miRNAs to 
signaling pathways are in good agreement with previous observations. A 
previous report showed that after the knockdown of the entire miR-183~96~182 
cluster, its associated genes were enriched in apoptosis and the 
PI3K/AKT/mTOR pathway (Weeraratne et al. 2012). In our analysis we predicted 
that cluster 47, miR-96, -182, and -183 were significantly associated in regulation 
of mTOR pathway (Table 4). We also found miRNAs in cluster 5 (miR-127, -136, 
-337, -370, 431, -432, -433, -493, -665, and -770) were significantly enriched in 
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the regulation of immune system associated pathways such as Fc epsilon RI (P < 
0.0004), T cell receptor (P < 0.0004), Toll-like receptor (P < 0.0011), Fc gamma 
R-mediated phagocytosis (P < 0.0023), and chemokine signaling pathways (P < 
0.012). In good agreement with our predictions, previous study showed that 
expression of miR-127 was increased in diffuse large B-cell lymphoma (Robertus 
et al. 2009) and also plays a role in inhibiting lung inflammation by targeting IgG 
Fcy receptorI (CD64) in an IgG immune complex model in-vivo (Xie et al. 2012). 
miR-493 regulated the expression of E2F1 in Lung cancer (Gu et al. 2014) which 
was involved in controlling Innate immune receptor Toll-like receptor3 in epithelial 
cells (Taura et al. 2012). MiR-136 is known to be involved in regulation of 
hematopoietic lineage(Yu et al. 2006) and erythropoiesis (Choong et al. 2007). 
 
In addition to good concordance of our prediction with previously known roles of 
miRNAs, reliability of our new method is further tested by functional validation of 
roles of miR-500 in regulation of MAPK pathway. Our data demonstrated that 
miR-500 function as a positive regulator of MAP2K1, upstream regulator of 
MAPKs, by directly targeting PPFIA1, a member of the LAR protein-tyrosine 
phosphatase-interacting protein (liprin) family. The previous studies showed that 
it was regulated by ERK2 in MAPK pathway leading to the inhibition of tumor 
invasion and progression (von Thun et al. 2012), and identified as a putative 
invasion suppressor gene in head and neck cancer (Tan et al. 2008). We further 
demonstrated that PPFIA1 is negative regulator of MAP2K1 as evidenced by 
activation of MAP2K1 upon depletion of PPFIA1 in melanoma and breast cancer 
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cell lines. Although precise mechanism of MAP2K1 regulation by PPFIA1 is 
currently unknown, our data clearly demonstrated that PPFIA1 is a novel 
regulator of MAP2K1.  Taken together with strong concordance of our analysis 
with previous studies, these data strongly supported the validity of our approach 
in finding novel functional roles of miRNAs in the regulation of signaling pathways 
and its potential for identifying novel regulators of signaling pathways.  
 
There are some limitations in our approaches. First, because we generated 
functional connection map between miRNAs and signaling pathways, extra 
experiments is necessary to identify direct targets of miRNAs that regulate 
signaling pathways.  Second, our approaches are limited by number of available 
high quality antibodies used in RPPA experiments. However, because many of 
antibodies used in RPPA experiment were pre-selected for signaling pathways 
important for cancer development and progression, substantial portion of 
signaling pathways is covered by our study. Moreover, antibodies available for 
RPPA experiments have been steadily increased to discover proteomic 
biomarkers in cancer (Hennessy et al. 2010; Meric-Bernstam et al. 2014).   
 
There is an limitation of correlation or association based approaches on miRNA 
target prediction. The correlation between miRNAs and target genes does not 
mean inferring their causal regulatory relationship. Because in this study we also 
used the correlation analysis to generate the indirect association between 
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miRNAs and proteins or biological pathways, it can be limited to examine the 
causality of miRNA-target genes. 
  
1. Concluding remarks and Future directions 
 
In this study we have developed a novel correlation based approach to 
characterize potential miRNA target pathways using ASM and PASM generated 
from genomic and proteomic data. Based on our approach, we found that miR-
500 cluster was enriched in MAPK pathway and performed in-vitro validation that 
miR-500 is involved in MAP2K1 phosphorylation in breast cancer and melanoma 
cells. In addition, we identified PPFIA1 as a direct target of miR-500 that 
regulates MAPK1 in the MAPK pathway.  
 
Our web-based database, miRPP, constructed with the procedures and 
approaches described in this study, may open up new opportunities to uncover 
novel molecular mechanisms regulated by miRNAs in cancer development. This, 
together with hypothesis-driven validation experiments as demonstrated with 
miR-500, paves the way for rapidly cataloging functional roles of miRNAs in 
signaling pathways in general. 
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2. Future works  
Expanding our approach to larger data sets 
With availability of The Cancer Genome Atlas data containing all three data sets 
(mRNAs, miRNAs, and proteins) from same tissues (Cancer Genome Atlas 
Research Network, 2014; Cancer Genome Atlas Research Network 2013; 
Cancer Genome Atlas Network, 2012), we expect our approach can be rapidly 
expanded to identify more functional links of miRNAs to signaling pathways in 
cancer type specific manner. Moreover, this can be also expanded to entire 
TCGA data to find generalizable connections of miRNAs to signaling pathways 
as seen in TCGA Pan-Cancer Project (Cancer Genome Atlas Research et al. 
2013b) (Hoadley et al. 2014). Table 14 shows the TCGA multiomics data sets 
which can be applicable with our approach in cBioPortal 
(http://www.cbioportal.org). Through the analysis of these massive data using our 
approaches we expect to elucidate the complicated miRNA regulatory 
association between miRNAs and signaling pathways. 
 
Improvement of prediction algorithms by including more high-throughput data.  
Since our current approach is based on correlation that does not reflect direct 
functional connections, we will include functional experimental data in future 
analysis to improve accuracy of our prediction methods.  These new data will 
include photoactivatable-ribonucleoside-enhanced crosslinking and 
immunoprecipitation (PAR-CLIP) (Bussey et al. 2006) assay, and high-
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throughput sequencing of RNAs isolated by crosslinking immunoprecipitation 
(HITS-CLIP) (Roschke et al. 2003) with the next-generation sequencing.  
 
Other non-cording RNAs 
With developing RNA-sequencing technology, huge amount of ncRNA data are 
produced. However their functions have not been clear and needed to be 
characterized. lncRNA data from cancer tissues are available in TCGA data 
portal (https://tcga-data.nci.nih.gov/tcga/). Therefore we can apply our approach 
to investigate lncRNA functions in signaling pathway using TCGA RNA-seq data 
in cancer. 
 
miRPP 
MiRPP currently provides the miRNA-correlated mRNA and RPPA protein 
profiles, indirection association between miRNAs and proteins, and the miRNA-
associated signaling pathways. For the future works in this system, we will 
update the analysis ouputs of TCGA data sets to verify our approach in large 
cancer data sets with the clinical information such as patient survival, tumor 
recurrence  and drug response. 
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3. In summary 
We have developed a novel correlation based approach to characterize 
potential miRNA target pathways using ASM and PASM generated from genomic 
and proteomic data. Based of our approach, we found that miR-500 cluster was 
enriched in MAPK pathway and performed in-vitro validation that miR-500 is 
involved in MEK1/2 phosphorylation in Breast cancer and melanoma cell. In 
addition, we identified PPFIA1 as a direct target of miR-500 that regulates 
MAP2K1 in the MAPK pathway. This approach can be applied to investigate 
unknown regulatory role of miRNAs in signaling pathway and miRNA regulatory 
networks in cancer. 
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